Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

not_yet_recruiting125%
completed250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_1

Combining Latency Reversing Agents to Address the HIV Reservoir

NCT07384624
completedphase_3

A Randomized, Placebo-controlled, Tourette Syndrome Study.

NCT00206323
completedphase_3

An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.

NCT00206336
terminatedphase_2

Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

NCT00296959

Clinical Trials (4)

Showing 4 of 4 trials
NCT07384624Phase 1

Combining Latency Reversing Agents to Address the HIV Reservoir

Not Yet Recruiting
NCT00206323Phase 3

A Randomized, Placebo-controlled, Tourette Syndrome Study.

Completed
NCT00206336Phase 3

An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.

Completed
NCT00296959Phase 2

Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4